Document:

Exhibit 10.6

 

FORM OF SHAREHOLDER SUPPORT AGREEMENT

 

THIS SHAREHOLDER SUPPORT
AGREEMENT, dated as of September 1, 2020 (the “Agreement”), by and
between Tottenham Acquisition I Ltd., a British Virgin Islands company (“Parent”),
and the undersigned, a stockholder (the “Holder”) of Clene Nanomedicine,
Inc., a Delaware corporation (the “Company”).

 

W I T N E S S E T H:

 

		A.	WHEREAS, the Parent, Chelsea Worldwide Inc., a Delaware corporation (the “Purchaser”),
the Company, Fortis Advisors LLC, as the representative of the Shareholders (the “Shareholders’ Representative”)
and Creative Worldwide Inc., a Delaware corporation (“Merger Sub”),
are entering into the Merger Agreement of even date herewith (as the same may be amended or supplemented from time to time, the
“Merger Agreement”) providing for the merger of Merger Sub, a wholly-owned
Subsidiary of the Purchaser with and into the Company (the “Merger”),
as a result of which the Company shall be the Surviving Corporation and shall continue its corporate existence under the laws of
the State of Delaware as a wholly owned Subsidiary of Purchaser;

 

		B.	WHEREAS, the Holder and its affiliates are the beneficial owners of [●], par value $0.0001
per share, of the Company (the “Company Stock”) (such shares of Company
Stock, the Holder’s and its affiliates’ “Existing Shares”
and such Existing Shares, together with any additional capital stock of the Company beneficially owned or acquired by the Holder
and its affiliates on or after the date hereof, the “Shares”);

 

		C.	WHEREAS, as an inducement and a condition to Parent entering into the Merger Agreement, the Holder
is entering into this Agreement with Parent; and

 

		D.	WHEREAS, the board of directors of the Company has approved the Merger Agreement and the transactions
contemplated thereby, and has consented to the execution and delivery of this Agreement in connection therewith, understanding
that the execution and delivery of this Agreement by the Holder is a material inducement and condition to Parent’s willingness
to enter into the Merger Agreement.

 

NOW, THEREFORE,
in consideration of the mutual covenants, representations, warranties and agreements contained herein, and intending to be legally
bound hereby, the parties agree as follows:

 

Article
I 

GENERAL

 

1.1 Definitions.
Capitalized terms used but not defined herein shall have the meanings set forth in the Merger Agreement.

 

Article
II 

AGREEMENT TO CONSENT AND VOTE

 

2.1 Agreement
to Deliver Written Consent. Prior to the Termination Date (as defined herein), the Holder irrevocably and unconditionally
agrees that Holder shall, promptly following the time at which the Registration Statement becomes effective under the Securities
Act (and, in any event, within two Business Days of such time), execute and deliver (or cause to be executed and delivered) the
Stockholder Written Consent, substantially in the form attached hereto as Exhibit A, pursuant to the Company’s Amended and
Restated Certificate of Incorporation covering all of the Shares approving the Merger, adopting the Merger Agreement and approving
any other matters necessary for consummation of the transactions contemplated by the Merger Agreement, including the Merger (the
“Transaction Matters”).

 

     

     

    

 

2.2 Agreement
to Vote. Prior to the Termination Date, the Holder irrevocably and unconditionally agrees that Holder shall, at any meeting
of the stockholders of the Company (whether annual or special and whether or not an adjourned or postponed meeting), however called,
appear at such meeting or otherwise cause the Shares to be counted as present thereat for purpose of establishing a quorum and
vote (or consent), or cause to be voted at such meeting (or validly execute and return and cause such consent to be granted with
respect to), all Shares in favor of the Transaction Matters.

 

Article
III 

ADDITIONAL AGREEMENTS

 

3.1 Waiver
of Appraisal Rights; Litigation. To the full extent permitted by law, the Holder hereby irrevocably and unconditionally waives,
and agrees not to exercise, any rights of appraisal (including under Section 262 of the DGCL), any dissenters’ rights and
any similar rights relating to the Merger that the Holder may directly or indirectly have by virtue of the ownership of any Shares.
The Holder further agrees not to commence, join in, facilitate, assist or encourage, and agrees to take all actions necessary
to opt out of any class in any class action with respect to, any claim, derivative or otherwise, against Parent, Purchaser, Merger
Sub, or the Company or any of their respective affiliates and each of their successors or directors relating to the negotiation,
execution or delivery of this Agreement or the Merger Agreement or the consummation of the transactions contemplated hereby or
thereby, including any claim (a) challenging the validity of, or seeking to enjoin the operation of, any provision of this
Agreement or (b) alleging a breach of any fiduciary duty of the board of directors of the Company in connection with this
Agreement, the Merger Agreement or the transactions contemplated hereby or thereby, and hereby irrevocably waives any claim or
rights whatsoever with respect to any of the foregoing.

 

3.2 Retention
of Shares. The Holder agrees that the Holder shall not, prior to the Termination Date, offer for sale, sell, short sell, transfer,
tender, pledge, encumber, assign, or otherwise dispose of, or grant a proxy with respect to, any of the Holder’s Shares
(each a “Transfer”). Any Transfer violation of this Agreement shall
be void ab initio.

 

3.3 Fiduciary
Duties. The Holder is entering into this Agreement solely in its capacity as the record or beneficial owner of the Shares.
The taking of any actions (or failures to act) by the Holder’s designees serving as a director of the Company shall not
be deemed to constitute a breach of this Agreement.

 

Article
IV 

REPRESENTATIONS AND WARRANTIES

 

4.1 Representations
and Warranties. The Holder hereby represents and warrants as follows:

 

(a) Ownership.
To the Holder’s knowledge, the Holder has, with respect to the Existing Shares, and at all times during the term of this
Agreement will continue to have, beneficial ownership of, good and valid title to and full and exclusive power to deliver written
consents, vote, issue instructions with respect to the matters set forth in Article II, agree to all of the matters set forth in
this Agreement and to Transfer the Shares. The Existing Shares constitute all of the shares of Company Stock owned of record or
beneficially by the Holder as of the date hereof. Other than this Agreement and the Second Amended and Restated Voting Agreement,
dated August 10, 2020, between the Company, the Holder and certain other shareholders of the Company, there are no agreements or
arrangements of any kind, contingent or otherwise, to which the Holder is a party presently obligating the Holder to Transfer or
cause to be Transferred to any person any of the Shares, and no person presently has any contractual or other right or obligation
to purchase or otherwise acquire any of the Shares.

 

    2

     

    

 

(b) Organization;
Authority. The Holder is a corporation duly organized, validly existing and in good standing under the Laws of the State of
Delaware. The Holder is not in violation of any of the provisions of the Holder’s certificate of limited partnership, partnership
agreement or comparable organizational documents, as applicable. The Holder has full power and authority and is duly authorized
to make, enter into and carry out the terms of this Agreement and to perform its obligations hereunder. This Agreement has been
duly and validly executed and delivered by the Holder and (assuming due authorization, execution and delivery by Parent) constitutes
a valid and binding agreement of the Holder, enforceable against the Holder in accordance with its terms, and no other action is
necessary to authorize the execution and delivery by the Holder or the performance of the Holder’s obligations hereunder.

 

(c) No
Violation. The execution, delivery and performance by the Holder of this Agreement will not (i) violate any provision of any
statutory law; (ii) violate any order, judgment or decree applicable to the Holder or any of its affiliates or (iii) conflict with,
or result in a breach or default under, any agreement or instrument to which the Holder or any of its affiliates is a party or
any term or condition of its certificate of limited partnership, partnership agreement or comparable organizational documents,
as applicable, except where such conflict, breach or default would not reasonably be expected to, individually or in the aggregate,
have an adverse effect on the Holder’s ability to satisfy its obligations hereunder.

 

(d) Consents
and Approvals. The execution and delivery by the Holder of this Agreement does not, and the performance of the Holder’s
obligations hereunder will not, require the Holder or any of its affiliates to obtain any consent, approval, authorization or permit
of, or to make any filing with or notification to, any person or governmental Authority, except such filings and authorizations
as may be required under the Exchange Act and under the Holder’s organizational documents.

 

Article
V 

MISCELLANEOUS

 

5.1 Disclosure.
The Holder hereby authorizes the Parent and the Company to publish and disclose in any announcement or disclosure required by
the SEC and in the Registration Statement the Holder’s identity and ownership of the Shares and the nature of the Holder’s
obligations under this Agreement.

 

5.2 Termination.
This Agreement shall terminate at the earlier of (a) the date the Merger Agreement is terminated in accordance with its terms
and (b) the date on which the Merger is consummated (the “Termination Date”).

 

5.3 Amendment.
This Agreement may not be amended, modified or supplemented in any manner, whether by course of conduct or otherwise, except by
an instrument in writing specifically designated as an amendment hereto, signed on behalf of each of the parties in interest at
the time of the amendment.

 

5.4 Extension;
Waiver. At any time prior to the Effective Time, the parties hereto, may, to the extent legally allowed, (a) extend the time
for the performance of any of the obligations or other acts of the other party hereto, (b) waive any inaccuracies in the representations
and warranties contained herein or in any document delivered pursuant hereto and (c) waive compliance with any of the agreements
or contained herein. Any agreement on the part of a party hereto to any such extension or waiver shall be valid only if set forth
in a written instrument signed on behalf of such party, but such extension or waiver or failure to insist on strict compliance
with an obligation, covenant, agreement or condition shall not operate as a waiver of, or estoppel with respect to, any subsequent
or other failure.

 

    3

     

    

 

5.5 Expenses.
All fees and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the
party incurring such fees or expenses, whether or not the Merger is consummated.

 

5.6 Notices.
All notices and other communications hereunder shall be in writing and shall be deemed duly given (a) on the date of delivery
if delivered personally, or if by facsimile or email, upon confirmation of receipt, (b) on the first (1st) business day following
the date of dispatch if delivered utilizing a next-day service by a recognized next-day courier or (c) on the earlier of confirmed
receipt or the fifth (5th) business day following the date of mailing if delivered by registered or certified mail, return receipt
requested, postage prepaid. All notices hereunder shall be delivered to the addresses set forth below, or pursuant to such other
instructions as may be designated in writing by the party to receive such notice:

 

if to the Holder, to:

 

[Redacted]

 

and

 

if to Parent,

 

Tottenham Acquisition I Limited

[Redacted]

Attn: Jason Ma

Email: jma@norwichhk.com

 

With a copy (which shall not constitute
notice) to:

 

Lawrence Venick

Loeb & Loeb LLP

21st Floor, CCB Tower,

3 Connaught Road Central

Central, Hong Kong

Email: lvenick@loeb.com

 

5.7 Interpretation.
The parties have participated jointly in negotiating and drafting this Agreement. In the event that an ambiguity or a question
of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties, and no presumption
or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provision of this Agreement.
When a reference is made in this Agreement to Articles or Sections, such reference shall be to an Article or Section of this Agreement
unless otherwise indicated. The headings contained in this Agreement are for reference purposes only and shall not affect in any
way the meaning or interpretation of this Agreement. Whenever the words “include,” “includes” or “including”
are used in this Agreement, they shall be deemed to be followed by the words “without limitation.” References to “the
date hereof” shall mean the date of this Agreement. As used in this Agreement, the “knowledge”
of the Holder means the actual knowledge of the Holder or any officer of Holder, if applicable, after due inquiry, and the “knowledge”
of Parent means the actual knowledge of any of the officers of Parent after due inquiry. As used herein, (a) “business
day” means any day other than a Saturday, a Sunday or a day on which banks in New York, New York or Hong Kong
are authorized by Law or executive order to be closed, (b) the term “person”
means any individual, corporation (including not-for-profit), general or limited partnership, limited liability company, joint
venture, estate, trust, association, organization, governmental Authority or other entity of any kind or nature, and (c) an “affiliate”
of a specified person is any other person that directly, or indirectly through one or more intermediaries, controls, is controlled
by or is under common control with, such specified person; provided, however, that solely for purposes of this Agreement,
notwithstanding anything to the contrary set forth herein, neither the Company nor any of its Subsidiaries shall be deemed to
be a Subsidiary or affiliate of the Holder; provided, further, that, for the avoidance of doubt, any general partner
of the Holder shall be deemed an affiliate the Holder; and provided, further, that an affiliate of the Holder shall
include any investment fund, vehicle or holding company of which an affiliate serves as the general partner, managing member or
discretionary manager or advisor; and provided, further, that, notwithstanding the foregoing, an affiliate of the
Holder shall not include any portfolio company or other investment of the Holder or any affiliate of the Holder.

 

    4

     

    

 

5.8 Counterparts.
This Agreement may be executed in two or more counterparts (including by facsimile or other electronic means), all of which shall
be considered one and the same agreement and shall become effective when counterparts have been signed by each of the parties
and delivered to the other party, it being understood that all parties need not sign the same counterpart.

 

5.9 Entire
Agreement. This Agreement (including the documents and the instruments referred to herein) constitutes the entire agreement
among the parties and supersedes all prior agreements and understandings, both written and oral, among the parties with respect
to the subject matter hereof.

 

5.10 Waiver
of Jury Trial. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE
COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST
EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY SUIT, ACTION OR OTHER PROCEEDING
DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH PARTY
CERTIFIES AND ACKNOWLEDGES THAT: (I) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE,
THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF ANY ACTION, SUIT OR PROCEEDING, SEEK TO ENFORCE THE FOREGOING WAIVER, (II) EACH
PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (III) EACH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (IV)
EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS
SECTION 5.10.

 

5.11 Governing
Law; Jurisdiction.

 

(a) This
Agreement shall be governed and construed in accordance with the laws of the State of Delaware, without regard to any applicable
conflicts of law.

 

(b) Each
party agrees that it will bring any action or proceeding in respect of any claim arising out of or related to this Agreement or
the transactions contemplated hereby exclusively in the Specified Courts, and, solely in connection with claims arising under this
Agreement or the transactions that are the subject of this Agreement, (i) irrevocably submits to the exclusive jurisdiction of
the Specified Courts, (ii) waives any objection to laying venue in any such action or proceeding in the Specified Courts, (iii)
waives any objection that the Specified Courts are an inconvenient forum or do not have jurisdiction over any party and (iv) agrees
that service of process upon such party in any such action or proceeding will be effective if notice is given in accordance with
Section 5.6.

 

    5

     

    

 

5.12 Assignment.
Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by any of the parties hereto
(whether by operation of law or otherwise) without the prior written consent of the other party. Any purported assignment in contravention
hereof shall be null and void. Subject to the preceding sentence, this Agreement will be binding upon, inure to the benefit of
and be enforceable by the parties and their respective successors and assigns.

 

5.13 Specific
Performance. The parties hereto agree that irreparable damage would occur if any provision of this Agreement were not performed
in accordance with its specific terms or were otherwise breached. Accordingly, the parties shall be entitled to specific performance
of the terms of this Agreement, including an injunction or injunctions to prevent breaches of this Agreement or to enforce specifically
the performance of the terms and provisions hereof (including the Holder’s obligation to deliver the Stockholder Written
Consent), in addition to any other remedy to which they are entitled at law or in equity. Each of the parties hereby further waives
(a) any defense in any action for specific performance that a remedy at law would be adequate and (b) any requirement under any
law to post security or a bond as a prerequisite to obtaining equitable relief.

 

5.14 Severability.
Whenever possible, each provision or portion of any provision of this Agreement shall be interpreted in such manner as to be effective
and valid under applicable Law, but if any provision or portion of any provision of this Agreement is held to be invalid, illegal
or unenforceable in any respect under any applicable Law in any jurisdiction, such invalidity, illegality or unenforceability
shall not affect any other provision or portion of any provision in such jurisdiction, and this Agreement shall be reformed, construed
and enforced in such jurisdiction such that the invalid, illegal or unenforceable provision or portion thereof shall be interpreted
to be only so broad as is enforceable.

 

5.15 Delivery
by Facsimile or Electronic Transmission. This Agreement and any signed agreement or instrument entered into in connection
with this Agreement, and any amendments or waivers hereto or thereto, to the extent signed and delivered by means of a facsimile
machine or by e-mail delivery of a “.pdf” format data file, shall be treated in all manner and respects as an original
agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed version
thereof delivered in person. No party hereto or to any such agreement or instrument shall raise the use of a facsimile machine
or e-mail delivery of a “.pdf” format data file to deliver a signature to this Agreement or any amendment hereto or
the fact that any signature or agreement or instrument was transmitted or communicated through the use of a facsimile machine
or e-mail delivery of a “.pdf” format data file as a defense to the formation of a contract and each party hereto
forever waives any such defense.

 

[Signature Page Follows]

 

    6

     

    

 

IN WITNESS WHEREOF, the parties hereto,
intending to be legally bound hereby, have executed or caused this Agreement to be executed in counterparts, all as of the day
and year first above written.

 

	 	TOTTENHAM ACQUISITION I LTD.
	 	 	 
	 	By:	/s/ Jason Ma
	 	Name:  	Jason Ma
	 	Title:	Chief Executive Officer

 

[Signature Page to the Shareholder Support
Agreement]

 

    

     

    

 

	 	HOLDER:
	 	 
	 	United Therapeutics Corporation
	 	 
	 	By:	/s/ John S. Hess, Jr.
	 	Name:  	John S. Hess, Jr.
	 	Title:	EVP, Deputy General Counsel
	 	 	 
	 	General Resonance, LLC
	 	 	 
	 	By:	/s/ Merrill Bateman
	 	Name:	Merrill Bateman
	 	Title:	President & Chairman of the Board

 

[Signature Page to the Shareholder Support
Agreement]

 

    

     

    

 

EXHIBIT A

 

CLENE NANOMEDICINE, INC.

 

Written Consent of Stockholder in
Lieu of a Meeting

Pursuant to Section 228 of the Delaware General Corporation Law

 

The undersigned stockholder
(the “Consenting Holder”) of Clene Nanomedicine, Inc., a Delaware corporation
(the “Company”), being the holder as of the date of this written consent
(this “Written Consent”) of [●], par value $0.0001 per share,
of the Company (the “Shares”), acting pursuant to Section 228 of the
Delaware General Corporation Law (the “DGCL”) and as authorized by
Section 2.11 of the Bylaws of the Company (the “Company Bylaws”), hereby
irrevocably consents in writing to the following actions and the adoption of the following resolutions without a meeting of stockholders:

 

WHEREAS, the
Company has entered into the Agreement (the “Merger Agreement”), dated
as of September 1, 2020, by and among , Chelsea Worldwide Inc, a Delaware corporation (the “Purchaser”), Fortis
Advisors LLC, as the representative of the Shareholders (the “Shareholders’ Representative”), Tottenham
Acquisition I Ltd., a British Virgin Islands company (“the “Parent”), and Creative Worldwide, Inc., a
Delaware corporation (“Merger Sub”), a copy of which has been provided
to the undersigned Consenting Holder and is attached hereto as Annex A (capitalized terms used but not defined herein shall
have the meanings set forth in the Merger Agreement);

 

WHEREAS, pursuant
to the Merger Agreement, among other things, Merger Sub will merge with and into the Company, with the Company continuing as the
surviving corporation of the Merger (the “Merger”);

 

WHEREAS, the
Company’s Board of Directors has (i) determined that the Merger is fair to, and in the best interests of, the Company and
its stockholders, (ii) approved the Merger, (iii) approved and declared advisable entry into the Merger Agreement and the transactions
contemplated thereby and (iv) subject to the terms and conditions set forth in the Merger Agreement, resolved to recommend the
approval of the Merger Agreement to the Company’s stockholders;

 

WHEREAS, pursuant
to the terms and conditions of the Merger Agreement, each share of Company capital stock (other than any Excluded Shares and Appraisal
Shares) issued and outstanding immediately prior to the Effective Time shall be converted, in accordance with the procedures set
forth in the Merger Agreement, into the right to receive, without interest, the Merger Consideration;

 

WHEREAS, a Registration
Statement has been filed by Purchaser with the SEC pursuant to which the offer and sale of shares of Purchaser Common Stock issuable
in the Merger are being registered with the SEC, which Registration Statement contains the Shareholder written consent statement,
and has become effective;

 

WHEREAS, pursuant
to Section 251 of the DGCL and Section 2.9 of the Company Bylaws, the Merger Agreement must be adopted by the holders of shares
representing a majority of the voting power of all then outstanding shares of (a) Company Common Stock and Company Preferred Stock
voting as a single class, (b) Company Preferred Stock voting as a separate class, (c) Company Series B Preferred Stock voting as
a separate class, (d) Company Series C Preferred Stock voting as a separate class, (e) the Company Series D Preferred Stock voting
as a separate class, and (f) the “Lead Investor” as defined in the Company’s Series D Preferred Stock Purchase
Agreement;

 

    

     

    

 

WHEREAS, pursuant
to Section 228 of the DGCL and Section 2.11 of the Company Bylaws, the Company’s stockholders may act by written consent;
and

 

WHEREAS, as
of the date hereof, the Shares represent approximately [_]% of the aggregate voting power of the issued and outstanding shares
of [______];

 

WHEREAS, as
of the date hereof, the Shares represent [all] of the voting power of the issued and outstanding shares of Company Series B Preferred
Stock as a separate class;

 

WHEREAS, upon
the execution and delivery of this written consent, the Requisite Stockholder Approval shall have been obtained in accordance with
to Section 251 of the DGCL, the Company Charter and the Bylaws;

 

NOW, THEREFORE,
BE IT RESOLVED, that the Merger Agreement and the Merger and the transactions contemplated thereby are hereby adopted and approved
by the Consenting Holder with the same force and effect as if the Stockholders had taken such action at a meeting of the stockholders
of the Company;

 

FURTHER RESOLVED,
signatures to this Written Consent transmitted by facsimile or PDF copy shall be deemed original signatures for all purposes,
and such execution and transmission shall be considered valid, binding and effective for all purposes.

 

This Written Consent
shall be effective as of the execution and delivery of this Written Consent in accordance with the terms of the Merger Agreement,
shall be filed with the book in which proceedings of meetings of the stockholders of the Company are recorded and shall be treated
for all purposes as action taken at a meeting.

 

[Signature page follows]

 

    

     

    

 

IN WITNESS WHEREOF, the undersigned
has executed this Written Consent on this __ day of _______ , 2020.

 

	 	[HOLDER]
	 	 
	 	By:	               
	 	Name:  	[●]
	 	Title:	[●]

 

    

     

    

 

Annex A

 

Merger AgreementExhibit 10.7

 

Execution Version

 

INITIAL
SHAREHOLDERS Forfeiture Agreement

 

This Initial Shareholder
Forfeiture Agreement (this “Agreement”) is entered into as of the 2nd
day of September, 2020, by and among Tottenham Acquisition I Ltd., a British Virgin Islands company (the “Parent”),
Clene Nanomedicine, Inc., a Delaware corporation (the “Company”) and the Parent’s Initial Shareholders
(the “Holders”). Capitalized terms used but not defined herein shall
have the meanings ascribed to them in the Merger Agreement (as defined below).

 

W I T N E S S E T H:

 

WHEREAS, the Holders
currently collectively hold 1,150,000 insider shares of the Parent (the “Shares”);

 

WHEREAS, the Shares
are currently held in escrow pursuant to the terms of that certain Stock Escrow Agreement, dated August 1, 2018, by and between
the Parent, Continental Stock Transfer & Trust Company, LLC, a New York corporation (the “Escrow
Agent”), and the initial shareholders of the Parent;

 

WHEREAS, concurrently
with the execution of this Agreement, the Parent and the Company, together with Chelsea Worldwide Inc., a Delaware corporation
and wholly-owned subsidiary of the Parent, and Creative Worldwide Inc., a Delaware corporation and wholly-owned subsidiary of the
Purchaser, have entered into that certain Merger Agreement, dated as of the date hereof (the “Merger
Agreement”), to effect the consummation of a business combination of the Parent with the Company; and

 

WHEREAS, the Holders
and Parent are entering in to this Agreement as a condition of, and as a material inducement for the Company to enter into and
consummate the transactions contemplated by the Merger Agreement.

 

NOW, THEREFORE, in
consideration of the foregoing and of the mutual covenants herein contained and other good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged, the parties hereto hereby agree as follows:

 

1. Cancellation
of Shares. No later than the Closing, the Parent shall instruct the Escrow Agent to cancel, and the Holders shall thereby
forfeit their Shares in the amount set forth in Schedule A, or in an aggregate amount of 750,000 Shares, in exchange
for no consideration.

 

2. Conversion of
Debt. The Holders and the Parent agree that, contingent upon the Closing and immediately prior to the Reincorporation Merger,
the Parent shall exchange all Indebtedness and other payables owed by it to the Sponsor or any of its Affiliates (the “Sponsor
Debt”) into a number of Parent Ordinary Shares equal to the aggregate amount of the Sponsor Debt divided by $10.

 

     

     

    

 

3. Representations. The
Company, the Parent and the Holders hereby represent and warrant as follows:

 

a.
Company Representations.

 

i) Authority;
Due Execution. The Company has all requisite power and authority and the legal capacity to execute, deliver and perform this
Agreement. The execution, delivery and performance of this Agreement has been duly authorized by all necessary corporate action
on the part of the Company. This Agreement has been duly executed and delivered by or on behalf of the Company and constitutes
a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except that
such enforceability may be limited by Creditors’ Rights.

 

ii) No Conflicts.
The execution and delivery of this Agreement by the Company does not, and the performance of this Agreement by the Company will
not (A) conflict with or violate any law applicable to the Company to the knowledge of the Company, or (B) result in the creation
of a lien or encumbrance on the Company’s assets pursuant to any note, bond, mortgage, indenture, contract, agreement, lease,
license, permit, franchise or other instrument or obligation to which the Company is a party or by which the Company or any of
the Company’s assets is bound or affected.

 

b.
Parent Representations.

 

i) Authority;
Due Execution. The Parent has all requisite power and authority and the legal capacity to execute, deliver and perform this
Agreement. The execution, delivery and performance of this Agreement has been duly authorized by all necessary corporate action
on the part of the Parent. This Agreement has been duly executed and delivered by or on behalf of the Parent and constitutes a
legal, valid and binding obligation of the Parent, enforceable against the Parent in accordance with its terms, except that such
enforceability may be limited by Creditors’ Rights.

 

ii) No Conflicts.
The execution and delivery of this Agreement by the Parent does not, and the performance of this Agreement by the Parent will not
(A) conflict with or violate any law applicable to the Parent to the knowledge of the Purchaser Parties, or (B) result in the creation
of a lien or encumbrance on the Parent’s assets pursuant to any note, bond, mortgage, indenture, contract, agreement, lease,
license, permit, franchise or other instrument or obligation to which the Parent is a party or by which the Parent or any of the
Parent’s assets is bound or affected.

 

c.
Holders Representations.

 

i) The Holders have all
requisite power and authority and the legal capacity to execute, deliver and perform this Agreement. This Agreement has been duly
executed and delivered by the Holders and constitutes a legal, valid and binding obligation of the Holders, enforceable against
the Holders in accordance with its terms, except that such enforceability may be limited by Creditors’ Rights.

 

ii) The Holders own,
of record and beneficially, and have good, valid and indefeasible title to the Shares free and clear of any and all mortgages,
pledges, security interests, encumbrances, liens or charges of any kind, except for those imposed on the Holders in connection
with the Parent’s initial public offering. Except for those agreements the Parent is a party to, there are no options, rights,
voting trusts, stockholder agreements or any other contracts or understandings to which the any Holder is a party or by which any
Holder or the Shares are bound with respect to the issuance, sale, transfer, voting or registration of the Shares.

 

    2

     

    

 

4. Notice.
All notices, request, demands, waivers and communications required or permitted to be given hereunder shall be in writing and
shall be delivered in person or mailed, certified or registered mail with postage prepaid, or sent by facsimile, as
follows:

 

if to the Company (following the Closing),
to:

 

Clene Nanomedicine, Inc.

6550 South Millrock Drive, Suite G50

Salt Lake City, Utah 84121

Attn: Rob Etherington

Facsimile No.: +1 (615) 676-9696

Telephone No.:+1 (801) 676-9695

Email: Rob@clene.com

 

with a copy to (which shall not constitute
notice):

 

Kirkland & Ellis LLP

601 Lexington Avenue

New York, NY 10022

Attn: James Hu

Facsimile No.: +1 (212) 446-6460

Telephone No.: +1 (212) 909-3341

Email: james.hu@kirkland.com

 

and

 

Kirkland & Ellis International LLP

26th Floor, Gloucester Tower

The Landmark

15 Queen’s Road Central

Hong Kong

Attn: Ben James

Facsimile No.: +852-3761-3301

Telephone No.: +852-3761-3412

Email: ben.james@kirkland.com

 

if to Parent

 

Tottenham Acquisition I Limited

Unit 902, Lucky Building

39-41 Wellington Street

Central, Hong Kong

Attn: Jason Ma

Email: jma@norwichhk.com

 

    3

     

    

 

with a copy to (which shall not constitute
notice):

 

Lawrence Venick

Loeb & Loeb LLP

21st Floor, CCB Tower,

3 Connaught Road Central

Central, Hong Kong

Telephone No.: +852-3923-1188

Email: lvenick@loeb.com

 

If to Holders, to Holders
at Holders’ last known mailing address specified in the Parent’s records, or to such other address as any party hereto
shall specify by notice in writing to the other parties in accordance with this Section. All such notices, requests, demands, waivers
and communications shall be deemed to have been received on the date when given unless mailed, in which case on the third Business
Day after the mailing.

 

5. Termination.
This Agreement shall terminate, and have no further force and effect, if the Merger Agreement is terminated in accordance
with its terms prior to the Closing.

 

6. Miscellaneous.
Sections 14.2 (Amendments; No Waivers; Remedies), 14.6 (No Assignment or Delegation), 14.7 (Governing Law), 14.8
(Counterparts; Facsimile Signatures), 14.10 (Severability) and 14.12 (Further Assurances) of the Merger Agreement shall apply
to this Agreement mutatis mutandis.

 

[Signature pages follow.]

 

    4

     

    

 

IN WITNESS WHEREOF, the Parent, Company
and Holders have entered into this Agreement as of the grant date specified above.

 

	 	Tottenham Acquisition I Ltd.
	 	 	 
	 	By:	/s/ Jason Ma
	 	Name:	Jason Ma
	 	Title:	Chief Executive Officer
	 	 	 
	 	Clene Nanomedicine, Inc.
	 	 	 
	 	By:	/s/ Rob Etherington
	 	Name:	Rob Etherington
	 	Title:	Chief Executive Officer and President
	 	 	 
	 	Norwich Investment Limited
	 	 	 
	 	By:	/s/ Jason Wong
	 	Name:	Jason Wong
	 	Title:	Authorized Signatory

 

	 	/s/ Jason Ma
	 	Jason Ma
	 	 
	 	/s/ Felix Wong
	 	Felix Wong
	 	 
	 	/s/ Satoshi Tominaga
	 	Satoshi Tominaga
	 	 
	 	/s/ Albert Lyu
	 	Albert Lyu
	 	 
	 	/s/ Estela Kuo
	 	Estela Kuo

 

[Signature page to Sponsor Forfeiture Agreement]

 

     

     

    

 

Schedule A - Forfeiture Amount

 

	Initial Shareholders	 	Founder Shares

 Forfeited	 
	Norwich Investment Limited	 	 	661,958	 
	Jason Ma	 	 	19,565	 
	Felix Wong	 	 	19,565	 
	Satoshi Tominaga	 	 	16,304	 
	Albert Lyu	 	 	16,304	 
	Estela Kuo	 	 	16,304	 
	TOTAL	 	 	750,000

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}]]